Liquid medicine film band-aid containing musk and preparation method of liquid medicine film band-aid

Abstract

The invention belongs to the technical field of medical nursing medical instruments, and relates to a musk-containing liquid medicine film band-aid and a preparation method thereof. According to the method, a musk substance is taken as a core, dragon's blood, frankincense, myrrh, borneol, safflower, catechu, pseudo-ginseng and free berberine are combined to form an active component, and the active component is combined with a polymer film-forming material, a plasticizer, a disinfectant, a penetration enhancer and the like to prepare a liquid wound nursing product capable of being sprayed or brushed. After the product is smeared on the surface of a wound, a layer of transparent, breathable and waterproof protective medicine film can be rapidly formed. The medical membrane not only plays a physical barrier role, but also can continuously release musk and other active ingredients, and realizes multiple effects of quickly stopping bleeding, easing pain, diminishing inflammation, promoting blood circulation to remove blood stasis and promoting healing. Compared with a traditional product, the device is suitable for irregular wounds, joints and other movable parts, and the application scene is wider; frequent replacement is not needed, and use is more convenient; edge warping is avoided, wound surface traction is avoided, and the comfort is higher.

Description

Technical Field

[0001] This invention belongs to the field of medical care and pharmaceutical technology, and relates to a liquid medicated film bandage containing musk and its preparation method. Background Technology

[0002] Currently, the most widely used adhesive bandages are ordinary liquid bandages and traditional cloth bandages. Ordinary liquid bandages mainly serve as a physical barrier, and although they can perfectly adhere to the wound, their therapeutic effects in relieving pain and promoting blood circulation are not ideal. Traditional cloth bandages mainly provide a moist healing environment for the wound, and although they have a slight analgesic effect, their breathability and waterproofness are generally poor, and they can cause a foreign body sensation when applied, easily leading to skin allergies and poor adhesion to joints, thus limiting their use.

[0003] Therefore, the present invention provides a musk-containing liquid medicated film bandage and its preparation method to solve the above problems. Summary of the Invention

[0004] The purpose of this invention is to overcome the shortcomings of the prior art and propose a musk-containing liquid medicated film bandage and its preparation method. This method combines the efficacy of traditional Chinese medicine musk with modern liquid bandage technology, achieving multiple effects such as rapid hemostasis, analgesia, anti-inflammation, blood circulation promotion and blood stasis removal, and promoting healing. On the other hand, it broadens the application scenarios of bandages, especially suitable for the treatment of joint areas, irregular wounds, and the initial stage of sports injuries.

[0005] To achieve the above objectives, the present invention provides the following technical solution: In a first aspect, the present invention provides a musk-containing liquid medicated film bandage, comprising active ingredients, film-forming materials, solvents, plasticizers, disinfectants, and penetration enhancers; the active ingredients comprise the following parts by weight of medicinal extracts: 1-5 parts of dragon's blood, 0.01-0.1 parts of musk-like substances, 0.5-2 parts of frankincense, 0.5-2 parts of myrrh, 0.5-2 parts of borneol, 0.5-2 parts of safflower, 1-3 parts of catechu, 1-5 parts of Panax notoginseng, and 0.8-2 parts of free berberine.

[0006] Specifically, the active ingredient is the core functional ingredient of this invention; The musk-like substances include natural musk, high-purity artificial musk, or muscone. However, from the perspective of protecting wild animals and ensuring product quality stability, high-purity artificial musk or muscone is preferred, as their pharmacological effects are basically the same as those of natural musk. Because the musk-like substances have strong medicinal effects, their dosage is extremely small. More specifically, the components of the active ingredients can form different combinations of effects: 1. Blood-activating and stasis-removing combination: Dragon's blood, safflower, Panax notoginseng, frankincense, and myrrh, as the core components for activating blood and removing stasis, can powerfully clear stagnant blood and eliminate swelling; 2. Collateral-clearing and pain-relieving combination: The penetrating properties of musk and borneol can guide the other drugs directly to the affected area and quickly exert an analgesic effect; 3. Hemostasis and tissue regeneration combination: Dragon's blood and catechu can both activate blood and stop bleeding, promoting wound healing.

[0007] Further, the amount of film-forming material is 8-15 parts by weight, the amount of solvent is 60-80 parts by weight, the amount of plasticizer is 2-5 parts by weight, the amount of disinfectant is 0.1-0.5 parts by weight, and the amount of penetration enhancer is 0.1-1 parts by weight.

[0008] Specifically, the film-forming material, solvent, plasticizer, disinfectant, and penetration enhancer are all made from medical-grade standard raw materials.

[0009] Furthermore, the film-forming material is a mixture of PVA and PVP.

[0010] Specifically, a mixture of PVA and PVP is preferred (it can be replaced with other types that meet clinical needs, such as one or more plasticizers including nitrocellulose, polyvinyl butyral, and acrylic resin, depending on the actual situation). The PVP, as the main film-forming material, can not only regulate the dissolution rate of the film, but also has strong adhesion and high film-forming flexibility. The PVA, as the auxiliary film-forming material, has strong film-forming ability and is not easily broken. Compared with the two individual components, the composite material is more balanced and superior in terms of biocompatibility, adhesion performance, dissolution performance and mechanical properties.

[0011] Furthermore, in the mixture of PVA and PVP, the mass ratio of PVA to PVP ranges from 1:1.5 to 1:4.

[0012] Specifically, the mass ratio of PVA and PVP allows the film formation time to be controlled within 2-5 minutes.

[0013] Furthermore, the solvent includes a first solvent and a second solvent; the first solvent is an ethanol preparation with a volume fraction of 75%, and the second solvent is distilled water.

[0014] Specifically, the 75% ethanol preparation is used as the extraction solvent to prepare the alcohol extract. On the one hand, this facilitates the full dissolution and dispersion of various lipid-soluble active ingredients, improving the extraction efficiency of the active ingredients. On the other hand, the 75% ethanol preparation can evaporate quickly, accelerating the rapid film formation of the drug solution while disinfecting the affected area (the 75% ethanol preparation can be replaced with other types that meet clinical needs, such as ethyl acetate, depending on the actual situation).

[0015] The distilled water, a commonly used solvent in clinical drug preparation, can accelerate the dispersion of the film-forming material.

[0016] More specifically, in the process of preparing the medicated film patch, rapid and thorough stirring is required to ensure complete dissolution of the film-forming material, which causes the preparation to become slightly heated. Since the 75% ethanol preparation added is flammable, the temperature must be strictly controlled to ensure the safety of the operation process.

[0017] Secondly, the present invention provides a method for preparing a musk-containing liquid medicated film bandage, such as... Figure 1 As shown, follow these steps: S1. Pre-treat the extracts of each medicinal material to prepare the active ingredients; S2. Prepare the film-forming material, and add the plasticizer and disinfectant to the film-forming material in sequence to obtain a modified film-forming material; S3. Add the active ingredient to the modified film-forming material, stir and mix, and then add a penetration enhancer to prepare a drug film slurry; S4. After homogenizing, degassing, and filtering the medicated film slurry, the filling and packaging processes are carried out in sequence to produce the finished product.

[0018] Specifically, in S3, the process parameter control standards for the medicated film adhesive are: viscosity range 1500-3000cps (tolerance ±50cps), solid content 15%-25% (tolerance ±1%), and pH value 5.0-7.0 (tolerance ±0.2).

[0019] Furthermore, the specific operation of S1 is as follows: S1.1 Weigh a specific mass fraction of the musk-like substance and borneol, and place them in the 75% ethanol preparation by volume, and stir gently until fully dissolved to obtain ethanol extract 1; S1.2 Weigh specific mass fractions of the frankincense and myrrh and process them into micro powder. Mix them and place them in the 75% ethanol preparation. Reflux extraction and filtration are performed sequentially to obtain ethanol extract 2. S1.3 Weigh a specific mass fraction of the free berberine and add it to the 75% ethanol preparation. Heat at low temperature until completely dissolved to prepare ethanol extract solution 3. S1.4. Mix and stir the alcohol extract 1, alcohol extract 2 and alcohol extract 3 to obtain an alcohol extract fluid extract; S1.5 Weigh specific mass portions of the aforementioned bloodwort, safflower, notoginseng, and catechu, mix them, add water, and decoct several times. Filter the resulting decoction, heat it again, and concentrate it into a thick paste to obtain an aqueous extract.

[0020] Specifically, the frankincense and myrrh extracts are processed sequentially using airflow pulverization and impact crushing technologies to ensure that the particle size of the frankincense and myrrh does not exceed 200 mesh, resulting in a mixed micro powder; the combined use of these two technologies is beneficial to improving the transdermal absorption rate of the drug. The reflux extraction device is a combined system of "heating-extraction-condensation-temperature control", and the solvent used is a fat-soluble solvent (such as 70%-80% ethanol aqueous solution). The solid-liquid ratio of the mixed micro powder to the fat-soluble solvent is 1:10-1:12 (the solid-liquid ratio can be adjusted between 1:10-1:15 according to actual needs). More specifically, in S1.4, the water-adding and decoction process must be repeated 2-3 times, with each decoction lasting 1 hour. After the decoction process is completed, the decoction obtained each time is combined and filtered.

[0021] Furthermore, the specific operation of S2 is as follows: S2.1 Weigh a specific amount of the PVA, place it in an appropriate amount of the distilled water, and soak it until it swells. S2.2 The PVA in the swollen state is heated in a water bath, and stirred until completely dissolved during the heating process to obtain a PVA solution; S2.3 Weigh a specific amount of the PVP, disperse it with an appropriate amount of distilled water, and stir continuously to dissolve it into a gel to obtain a PVP solution. S2.4. Mix the PVA solution and PVP adhesive, and stir until homogeneous to obtain the film-forming material; S2.5. A specific amount of the plasticizer and disinfectant are added to the film-forming material in sequence, and the mixture is stirred to form the modified film-forming material.

[0022] Specifically, the plasticizer acts by inserting itself between polymer chains to weaken inter-chain forces. When used in conjunction with the film-forming material, the plasticizer increases the flexibility of the film, preventing it from becoming too brittle and making it adhere better to the skin and less prone to cracking. Furthermore, adding the plasticizer after the film-forming material is prepared ensures the solubility of PVA and PVP. The preferred plasticizer is a mixture of glycerol and propylene glycol (which may be replaced with other types that meet clinical needs, such as one or more plasticizers including diethyl phthalate, castor oil, and camphor, depending on the actual situation). More specifically, the disinfectant is a modern disinfectant ingredient that can kill bacteria at the wound site and prevent infection. It is a modern supplement to the active ingredient and works synergistically with it in terms of efficacy. The preferred disinfectant is benzalkonium chloride or povidone-iodine (other types that meet clinical needs, such as triclosan, may be used depending on the actual situation).

[0023] Furthermore, the specific operation of S3 is as follows: S3.1 Add the water-extracted fluid extract described in S1 to the modified film-forming material, and then stir. While stirring, add the alcohol-extracted fluid extract described in S1. After mixing, a drug-containing film-forming matrix material is obtained. S3.2. A specific amount of penetration enhancer is added to the drug-containing film-forming matrix material, and the mixture is stirred to obtain the drug film paste.

[0024] Specifically, since the musk-like substances contained in the alcohol extract are expensive and the aroma components are volatile, adding them in the later stages of the preparation process can not only reduce losses, but also ensure their uniform distribution in the drug film paste.

[0025] More specifically, the penetration enhancer temporarily alters the barrier function of the stratum corneum, thereby assisting the active pharmaceutical ingredient to penetrate the skin barrier and infiltrate the damaged dermis. If added too early, it may interact unnecessarily with film-forming materials or other components, affecting product stability or film-forming performance. Furthermore, adding the penetration enhancer at the final stage ensures that its function is preserved to the maximum extent, promoting the absorption of the active ingredient. The preferred penetration enhancer is azone (which can be replaced with other types that meet clinical needs, such as aminophenazone, depending on the actual situation). In addition, depending on actual needs, coloring agents or fragrances may be added in step S3.2 in addition to penetration enhancers to optimize the user experience of the present invention.

[0026] Furthermore, the specific operation of S4 is as follows: S4.1 The medicated film slurry described in S3 is subjected to homogenization, degassing and filtration treatment in sequence; S4.2 In a sterile cleanroom, the medicated film mortar is filled into a specific container and packaged to form a finished product.

[0027] Specifically, the homogenization process involves homogenizing the drug film paste described in S4.1 using a high-pressure homogenizer. This operation ensures that all components are evenly distributed, thereby obtaining a stable drug film system. Degassing treatment involves sending the drug solution into a vacuum degassing tank to remove air bubbles introduced during stirring and homogenization under negative pressure. This operation can prevent pores from forming after film formation. The filtration process is performed using a drug solution filter (preferably a 0.45 μm microporous membrane) to ensure that the drug solution is clear and sterile; More specifically, the specific operation of S4.2 is as follows: S4.21. In a sterile cleanroom, the pharmaceutical film slurry is loaded into a medicine bottle made of brown neutral borosilicate glass and equipped with a capillary brush or spray head. S4.22. Seal, label, and box the medicine bottle.

[0028] In S4.21, the light-shielding rate of the medicine bottle is ≥90%. Depending on the actual situation, it can be replaced with other containers that meet the light-shielding requirements (such as light-shielding plastic bottles with PP or HDPE as the base material). In S4.22, after the finished product is sealed and packaged, it shall be labeled and boxed in sequence. The outer packaging shall indicate the product name, ingredients, efficacy, usage, production date and expiration date.

[0029] In addition, the finished product must be tested for effectiveness and safety. The specific procedures are as follows: Efficacy testing: 5% of the finished product from each batch is randomly sampled and the active ingredients in the finished product are quantitatively analyzed using modern analytical methods (such as high performance liquid chromatography) to ensure the stability of the content of each component in the medicated film patch, and clinical efficacy trials are conducted.

[0030] Safety testing: 5% of each batch of the finished product is randomly sampled for skin irritation and allergy testing.

[0031] Compared with the prior art, the present invention has the following beneficial effects: Firstly, from the perspectives of traditional pharmacology and modern research, musk-like substances possess the following effects: 1. Musk has a strong effect of promoting blood circulation and clearing the meridians. For closed soft tissue injuries (such as sprains and contusions) accompanied by bruising and swelling, it can promote local blood circulation, accelerate the absorption of bruising, and thus reduce swelling and relieve pain; 2. Musk-like substances have an inhibitory effect on some bacteria (such as Staphylococcus aureus and Escherichia coli), and can reduce inflammation and prevent wound infection; 3. Musk ketones can stimulate the healing and regeneration of biological tissues (such as skin, connective tissue, and vascular endothelium) under low concentration conditions. This invention applies musk to modern liquid bandages, enabling modern liquid bandages to have analgesic, antibacterial, and healing-promoting effects.

[0032] Secondly, this invention uses dragon's blood, frankincense, myrrh, safflower, catechu, borneol, Panax notoginseng, and free berberine as active ingredients to achieve a synergistic effect across the entire chain of "hemostasis, blood stasis removal, pain relief, antibacterial properties, healing promotion, and transdermal enhancement." This aligns with the traditional Chinese medicine principle of "treating both the symptoms and the root cause" in formulation, while also enhancing its clinical applicability through modern pharmacological mechanisms. Compared to traditional plasters and ordinary liquid bandages, it is not only suitable for common cuts and abrasions but also plays a role in sports medicine and the prevention of everyday injuries (such as sprains and early-stage muscle soreness), thus broadening its application scenarios.

[0033] Furthermore, the rapid film-forming technology of this invention effectively isolates the wound from external bacteria. The disinfectant added to the film kills bacteria on the wound and prevents infection. The added penetration enhancer helps the active ingredients in the film penetrate the skin barrier and reach the dermal damage area.

[0034] These technologies achieve a triple effect of "highly effective treatment with traditional Chinese medicine + physical isolation and protection + modern disinfection".

[0035] Third, after adhering to the surface of the wound, this invention forms a transparent and breathable film that can adapt to wounds of different locations and shapes, avoiding the problems of traditional adhesive tape peeling and falling off. It is especially suitable for irregular wounds and frequently used joints, effectively isolating water, bacteria, and dirt, and reducing the risk of wound infection. In addition, the formed film provides a moist healing environment for the wound (modern medicine has proven that a moist environment is more conducive to cell migration and growth than a dry scab, which can accelerate the healing process and reduce the chance of scar formation), and continuously and stably releases active ingredients to the wound, achieving long-term therapeutic effects.

[0036] Fourth, this invention can stably adhere to the wound for 3-5 days. The added plasticizer improves the extensibility and flexibility of the medicated film, providing patients with a comfortable and convenient user experience. Attached Figure Description

[0037] The accompanying drawings are incorporated in and form part of this specification, and together with the description serve to explain the principles of the invention.

[0038] To more clearly illustrate the technical solutions in the embodiments of the present invention or the prior art, the drawings used in the description of the embodiments or the prior art will be briefly introduced below. Obviously, for those skilled in the art, other drawings can be obtained based on these drawings without creative effort.

[0039] Figure 1 This is a flowchart of the preparation method of the present invention. Detailed Implementation

[0040] Exemplary embodiments will now be described in detail. The embodiments described in the following exemplary embodiments do not represent all embodiments consistent with the present invention. Rather, they are merely examples consistent with some aspects of the invention as detailed in the appended claims.

[0041] To enable those skilled in the art to better understand the technical solutions of the present invention, the present invention will be further described in detail below with reference to embodiments.

[0042] Example 1 This embodiment provides a method for preparing a musk-containing liquid medicated film bandage, specifically as follows: S1. Pre-treat the raw materials of the extracts from each of the medicinal herbs to prepare the active ingredients. Specific steps are as follows: S1.1 Weigh 0.05 parts by weight of the musk-like substance and 0.5 parts by weight of borneol, and place them in 20 parts by weight of 75% ethanol preparation. Stir gently until fully dissolved to obtain ethanol extract 1. S1.2 Weigh 0.5 parts by weight each of frankincense and myrrh, process them into micro powder, mix them, and place them in 20 parts by weight of 75% ethanol preparation. Reflux extraction and filtration are performed sequentially to obtain ethanol extract 2. S1.3 Weigh 0.8 parts by weight of the free berberine and add it to 10 parts by weight of 75% ethanol preparation. Heat in a water bath at 40°C until completely dissolved to obtain ethanol extract 3. S1.4. Mix the alcohol extract 1, alcohol extract 2 and alcohol extract 3 to obtain an alcohol extract fluid extract; S1.5 Weigh 1 part by weight of the blood dragon, 0.5 part by weight of safflower, 1.5 part by weight of Panax notoginseng and 1 part by weight of catechu, mix them and add purified water to decoct. Decoction is repeated for 1 hour each time, and the decoction is repeated 3 times. The decoction obtained from the 3 times is mixed, filtered and heated again until it is concentrated into a thick paste (the relative density is about 1.2-1.3 when measured at 50-60℃) to obtain the water extract.

[0043] S2. Prepare the film-forming material, and sequentially add the plasticizer and disinfectant to the film-forming material to obtain a modified film-forming material. Specific steps are as follows: S2.1 Weigh 0.8 parts by weight of the PVA and place it in 3 parts by weight of distilled water. Soak it at room temperature for 16-24 hours until it swells. S2.2. Heat the swollen PVA in a water bath to 90°C and stir until completely dissolved to obtain a clear and transparent PVA solution; S2.3 Weigh 3.2 parts by weight of the PVP and disperse it with 7 parts by weight of distilled water. Stir continuously to dissolve it into a colorless and transparent viscous colloid to obtain PVP solution. S2.4. Mix the PVA solution and PVP adhesive, and stir until homogeneous to obtain the film-forming material; S2.5. Add 1 part by mass of each of the glycerol, propylene glycol and benzalkonium chloride to the film-forming material in sequence, and stir to form the modified film-forming material.

[0044] S3. Add the active ingredient to the modified film-forming material, stir and mix, and then add a penetration enhancer to prepare a pharmaceutical film paste. Specific steps are as follows: S3.1 Add the water-extracted fluid extract from S1 to the modified film-forming material, and then stir vigorously and rapidly to make the water-extracted fluid extract and the modified film-forming material evenly mixed; while stirring, slowly add the alcohol-extracted fluid extract from S1 to avoid polymer flocculation caused by ethanol, and after mixing, obtain the drug-containing film-forming matrix material. S3.2 Add 0.1 parts by weight of the azone to the drug-containing film-forming matrix material, and stir to obtain the drug film paste.

[0045] S4. After homogenizing, degassing, and filtering the medicated film slurry, it is then filled and packaged sequentially to produce the finished product. The specific steps are as follows: S4.1 The medicated film slurry described in S3 is subjected to homogenization, degassing, and filtration treatment in sequence; S4.2 In a sterile cleanroom, the medicated film mortar is filled into brown neutral borosilicate glass and equipped with a capillary brush. After sealing and packaging, the labeling and boxing processes are carried out in sequence. The product name, ingredients, efficacy, usage, production date and expiration date are indicated on the outer packaging.

[0046] Clinical Case 1 Patient: Mr. Zhang, 35 years old, chef.

[0047] Chief complaint: The patient accidentally cut his left index finger with a knife while chopping vegetables. The wound was about 1.5 cm long and reached the dermis. There was active bleeding and severe pain.

[0048] After routine treatment including rinsing with clean water and applying sterile gauze to stop bleeding, the present invention is applied to the wound and surrounding area using a fine brush. The invention forms a thin film after 2 minutes, and the patient reported a significant reduction in pain within 1-2 minutes. On the first day after application, there was no increase in redness and swelling around the wound, and the pain was mild. On the third day, the wound edges began to heal, with no signs of infection. On the fifth day, the film naturally detached, the wound was basically healed, and the scar was flat and light in color. Compared to traditional adhesive bandages, this invention offers advantages in rapid pain relief, reduced pain during dressing changes, providing an observation window, and promoting healing quality, making it particularly suitable for hand injuries that require continued work.

[0049] Example 2 This embodiment provides a method for preparing a musk-containing liquid medicated film bandage, specifically as follows: S1. Pre-treat the raw materials of each medicinal herb extract and extract the active ingredients from them. Specific steps are as follows: S1.1 Weigh 0.01 parts by weight of the musk-like substance and 2 parts by weight of the borneol, and place them in 20 parts by weight of 75% ethanol preparation. Stir gently until fully dissolved to obtain ethanol extract 1. S1.2 Weigh 2 parts by weight each of frankincense and myrrh, process them into micro powder, mix them, and place them in 20 parts by weight of 75% ethanol preparation. Reflux extraction and filtration are performed sequentially to obtain ethanol extract 2. S1.3 Weigh 1.2 parts by weight of the free berberine and add it to 20 parts by weight of 75% ethanol preparation. Heat in a water bath at 40°C until completely dissolved to obtain ethanol extract 3. S1.4. Mix the alcohol extract 1, alcohol extract 2 and alcohol extract 3 to obtain an alcohol extract fluid extract; S1.5 Weigh 5 parts by weight of the blood dragon, 2 parts by weight of safflower, 1 part by weight of Panax notoginseng and 3 parts by weight of catechu, mix them and add purified water to decoct. Decoction is repeated twice for 1 hour each time. Mix the decoctions obtained from the two decoctions, filter them and heat them again until they are concentrated into a thick paste (the relative density is about 1.2-1.3 when measured at 50-60℃) to obtain the water extract.

[0050] S2. Prepare the film-forming material, and then add the plasticizer and disinfectant to the film-forming material to obtain a modified film-forming material. The specific steps are as follows: S2.1 Weigh 6 parts by weight of the PVA and place it in 8 parts by weight of distilled water. Soak it at room temperature for 16-24 hours until it swells. S2.2. Heat the swollen PVA in a water bath to 90°C and stir until completely dissolved to obtain a clear and transparent PVA solution; S2.3 Weigh 9 parts by weight of the PVP and disperse it with 12 parts by weight of distilled water. Stir continuously to dissolve it into a colorless and transparent viscous colloid to obtain PVP solution. S2.4. Mix the PVA solution and PVP adhesive, and stir until homogeneous to obtain the film-forming material; S2.5. Add 2 parts by weight each of glycerol and propylene glycol, and 0.05 parts by weight of povidone-iodine to the film-forming material in sequence, and stir to form the modified film-forming material.

[0051] S3. Add the active ingredient to the modified film-forming material, stir and mix, and then add a penetration enhancer to prepare a pharmaceutical film paste. Specific steps are as follows: S3.1 Add the water-extracted fluid extract from S1 to the modified film-forming material, and then stir vigorously and rapidly to make the water-extracted fluid extract and the modified film-forming material evenly mixed; while stirring, slowly add the alcohol-extracted fluid extract from S1 to avoid polymer flocculation caused by ethanol, and after mixing, obtain the drug-containing film-forming matrix material. S3.2 Add 1 part by mass of the azone to the drug-containing film-forming matrix material, and stir to obtain the drug film paste.

[0052] S4. After homogenizing, degassing, and filtering the medicated film slurry, it is then filled and packaged sequentially to produce the finished product. The specific steps are as follows: S4.1 The medicated film slurry described in S3 is subjected to homogenization, degassing, and filtration treatment in sequence; S4.2 In a sterile cleanroom, the medicated film mortar is filled into brown neutral borosilicate glass and equipped with a spray nozzle. After sealing and packaging, the labeling and boxing processes are carried out in sequence. The product name, ingredients, efficacy, usage, production date and expiration date are indicated on the outer packaging.

[0053] Clinical Case 2 Patient: Li, 18 years old, student.

[0054] Chief complaint: The patient fell while playing basketball, and the front of the right tibia struck the ground, resulting in rapid swelling, bruising, significant tenderness, and limited mobility in the affected area.

[0055] In addition to the standard treatment of applying ice within 24 hours of injury, applying heat after 24 hours, and taking oral medication to promote blood circulation and remove blood stasis, the patient applied this invention to the swollen and painful area after 24 hours. The invention forms a thin film after 4 minutes, and the patient reported a significant reduction in pain within 3-5 minutes. On the first day, the patient continuously felt relief from the swelling and pain. On the second day, the swelling began to subside, and the purplish-blue color of the skin lightened. By the fifth day, the pain had basically disappeared, most of the bruising had been absorbed, and activity had returned to normal.

[0056] For closed soft tissue injuries, this product, as a local drug delivery system, can directly and continuously deliver the blood-activating and stasis-removing effects of the active ingredients to the affected area, making it more targeted and convenient than simply taking oral medications or ointments.

[0057] Example 3 This embodiment provides a method for preparing a musk-containing liquid medicated film bandage, specifically as follows: S1. Pre-treat the raw materials of each medicinal herb extract and extract the active ingredients from them. Specific steps are as follows: S1.1 Weigh 0.03 parts by weight of the musk-like substance and 1.2 parts by weight of borneol, and place them in 15 parts by weight of 75% ethanol preparation. Stir gently until fully dissolved to obtain ethanol extract 1. S1.2 Weigh 1.2 parts by weight of each of the frankincense and myrrh, process them into micro powder, mix them, and place them in 20 parts by weight of 75% ethanol preparation. Perform reflux extraction once and filter to obtain ethanol extract 2. S1.3 Weigh 2 parts by mass of the free berberine and add it to 15 parts by mass of 75% ethanol preparation. Heat in a water bath at 40°C until completely dissolved to obtain ethanol extract 3. S1.4. Mix the alcohol extract 1, alcohol extract 2 and alcohol extract 3 to obtain an alcohol extract fluid extract; S1.5 Weigh 3 parts by weight of the blood dragon, 1.2 parts by weight of safflower, 5 parts by weight of Panax notoginseng and 2 parts by weight of catechu, mix them and add purified water to decoct. Decoction is repeated for 1 hour each time, and the decoction is repeated 3 times. The decoction obtained from the 3 times is mixed, filtered and heated again until it is concentrated into a thick paste (the relative density is about 1.2-1.3 when measured at 50-60℃) to obtain the water extract fluid extract.

[0058] S2. Prepare the film-forming material, and then add the plasticizer and disinfectant to the film-forming material to obtain a modified film-forming material. The specific steps are as follows: S2.1 Weigh 3 parts by weight of the PVA and place it in 6 parts by weight of distilled water. Soak it at room temperature for 16-24 hours until it swells. S2.2. Heat the swollen PVA in a water bath to 90°C and stir until completely dissolved to obtain a clear and transparent PVA solution; S2.3 Weigh 9 parts by weight of the PVP and disperse it with 14 parts by weight of distilled water. Stir continuously to dissolve it into a colorless and transparent viscous colloid to obtain PVP solution. S2.4. Mix the PVA solution and PVP adhesive, and stir until homogeneous to obtain the film-forming material; S2.5. Add 1.5 parts by weight each of glycerol and propylene glycol and 0.3 parts by weight of povidone-iodine to the film-forming material in sequence, and stir to form the modified film-forming material.

[0059] S3. Add the active ingredient to the modified film-forming material, stir and mix, and then add a penetration enhancer to prepare a pharmaceutical film paste. Specific steps are as follows: S3.1 Add the water-extracted fluid extract from S1 to the modified film-forming material, and then stir vigorously and rapidly to make the water-extracted fluid extract and the modified film-forming material evenly mixed; while stirring, slowly add the alcohol-extracted fluid extract from S1 to avoid polymer flocculation caused by ethanol, and after mixing, obtain the drug-containing film-forming matrix material. S3.2 Add 0.5 parts by weight of the azone to the drug-containing film-forming matrix material, and stir to obtain the drug film paste.

[0060] S4. After homogenizing, degassing, and filtering the medicated film slurry, it is then filled and packaged sequentially to produce the finished product. The specific steps are as follows: S4.1 The medicated film slurry described in S3 is subjected to homogenization, degassing, and filtration treatment in sequence; S4.2 In a sterile cleanroom, the medicated film mortar is filled into brown neutral borosilicate glass and equipped with a spray nozzle. After sealing and packaging, the labeling and boxing processes are carried out in sequence. The product name, ingredients, efficacy, usage, production date and expiration date are indicated on the outer packaging.

[0061] Clinical Case 3 Patient: Ms. Wang, 40 years old, housewife.

[0062] Chief complaint: Hot oil splashed onto the back of my right hand while cooking, causing a red spot and blister about 2cm x 3cm in size. The pain was severe and there was a burning sensation.

[0063] After rinsing the blisters with cold water (without puncturing them) and drying them, the patient applied the present invention to the blisters. Within 3 minutes, the liquid transformed into a film, and the burning sensation was significantly reduced after 2-3 minutes. The blisters were gradually absorbed in a sterile environment, and the film formed by the present invention remained intact. The patient could wash their hands normally, and their daily life was not affected. After 3 days, the film fell off after washing with water, revealing smooth new skin with minimal pigmentation.

[0064] For small, superficial second-degree burns, this product provides a near-ideal moist healing environment. Combined with the medicinal properties of musk, it achieves a triple effect of pain relief, infection prevention, and healing promotion.

[0065] The present invention also provides the recovery of wounds under the same conditions as in Example 1 when using traditional cloth bandages or ordinary liquid bandages, specifically: Comparative Example 1 This comparative example shows the wound recovery under the same conditions as in Example 1 when using a traditional cloth bandage. When the traditional cloth bandage was applied to the wound, the pain slightly decreased after 5-10 minutes; after the first day of use, there was slight redness and swelling around the wound, and the pain was still significant; after the third day of use, the wound edges had not healed and there was slight oozing; after the fifth day of use, the wound had begun to heal, with raised and darker scarring.

[0066] Comparative Example 2 This comparative example shows the wound recovery under the same conditions as in Example 1 when using a regular liquid bandage. After applying the regular liquid bandage to the wound, the surface of the medicated film was dry after 30 seconds and completely cured after 2-3 minutes; the pain slightly subsided after 4-7 minutes; after the first day of use, the area around the wound was slightly red, and the pain subsided slowly; after the third day of use, the edges of the wound partially healed, and there was a slight feeling of tightness; after the fifth day of use, the medicated film was manually peeled off, and the wound had healed, but a slightly raised scar remained.

[0067] The table below compares the clinical efficacy of Clinical Case 1 in this application with Comparative Cases 1 and 2: In summary, based on the experimental data above, we can conclude that: First, the film-forming efficiency of this invention is more balanced, avoiding the defect of "no film-forming protection" in traditional products and solving the problem of "surface drying ≠ complete curing" in ordinary liquid bandages; Second, the analgesic response speed of this invention is 2-5 times that of existing products, resulting in a better immediate user experience; Third, the healing process of this invention is relatively faster, while avoiding discomfort such as infection and tightness; Fourth, compared with the other two types of bandages, this invention not only has higher healing quality but also produces more aesthetically pleasing scars, and the medicated film is easier to peel off, avoiding secondary irritation of the wound.

[0068] The above description is merely a specific embodiment of the present invention, enabling those skilled in the art to understand or implement the invention. Various modifications to these embodiments will be readily apparent to those skilled in the art, and the general principles defined herein may be implemented in other embodiments without departing from the spirit or scope of the invention.

[0069] It should be understood that the present invention is not limited to the content already described above, and various modifications and changes can be made without departing from its scope. The scope of the present invention is limited only by the appended claims.

Claims

1. A liquid medicated film bandage containing musk, characterized in that, It includes active ingredients, film-forming materials, solvents, plasticizers, disinfectants, and penetration enhancers; the active ingredients include the following medicinal extracts in parts by weight: 1-5 parts of dragon's blood, 0.01-0.1 parts of musk, 0.5-2 parts of frankincense, 0.5-2 parts of myrrh, 0.5-2 parts of borneol, 0.5-2 parts of safflower, 1-3 parts of catechu, 1-5 parts of Panax notoginseng, and 0.8-2 parts of free berberine.

2. The musk-containing liquid medicated film bandage according to claim 1, characterized in that, The film-forming material is used in an amount of 8-15 parts by weight, the solvent in an amount of 60-80 parts by weight, the plasticizer in an amount of 2-5 parts by weight, the disinfectant in an amount of 0.1-0.5 parts by weight, and the penetration enhancer in an amount of 0.1-1 parts by weight.

3. The musk-containing liquid medicated film bandage according to claim 1, characterized in that, The film-forming material is a mixture of PVA and PVP.

4. The musk-containing liquid medicated film bandage according to claim 3, characterized in that, In the mixture of PVA and PVP, the mass ratio of PVA to PVP ranges from 1:1.5 to 1:

4.

5. The musk-containing liquid medicated film bandage according to claim 1, characterized in that, The solvent includes a first solvent and a second solvent; the first solvent is an ethanol preparation with a volume fraction of 75%, and the second solvent is distilled water.

6. A method for preparing a musk-containing liquid medicated film bandage according to any one of claims 1-5, characterized in that, Follow these steps: S1. Pre-treat the herbal extract to prepare the active ingredient; S2. Prepare the film-forming material, and add plasticizer and disinfectant to the film-forming material in sequence to obtain a modified film-forming material; S3. Add the active ingredient to the modified film-forming material, stir and mix, and then add the penetration enhancer to prepare the drug film slurry; S4. After homogenizing, degassing, and filtering the medicated film slurry, the filling and packaging processes are carried out in sequence to produce the finished product.

7. The method for preparing a musk-containing liquid medicated film bandage according to claim 6, characterized in that, The specific operation of S1 is as follows: S1.1 Weigh a specific mass fraction of the musk-like substance and borneol, and place them in the 75% ethanol preparation. Stir gently until fully dissolved to obtain ethanol extract 1. S1.2 Weigh specific mass fractions of the frankincense and myrrh and process them into micro powder. Mix them and place them in the 75% ethanol preparation. Reflux extraction and filtration are performed sequentially to obtain ethanol extract 2. S1.3 Weigh a specific mass fraction of the free berberine and add it to the 75% ethanol preparation. Heat at low temperature until completely dissolved to obtain ethanol extract 3. S1.

4. Mix and stir the alcohol extract 1, alcohol extract 2 and alcohol extract 3 to obtain an alcohol extract fluid extract; S1.5 Weigh specific mass amounts of the aforementioned bloodwort, safflower, notoginseng, and catechu, mix them, add water and decoct. Filter the resulting decoction and heat it again to concentrate it into a thick paste to obtain an aqueous extract.

8. The method for preparing a musk-containing liquid medicated film bandage according to claim 6, characterized in that, The specific operation of S2 is as follows: S2.1 Weigh a specific mass fraction of the PVA, place it in an appropriate amount of distilled water, and soak it until it swells. S2.2 The PVA in the swollen state is heated in a water bath, and stirred until completely dissolved during the heating process to obtain a PVA solution; S2.3 Weigh a specific mass fraction of the PVP, disperse it with an appropriate amount of distilled water, and stir continuously to dissolve it into a gel to obtain a PVP adhesive solution. S2.

4. Mix the PVA solution and PVP adhesive, and stir until homogeneous to obtain the film-forming material; S2.

5. A specific mass fraction of the plasticizer and disinfectant are added to the film-forming material in sequence, and the mixture is stirred to obtain the modified film-forming material.

9. The method for preparing a musk-containing liquid medicated film bandage according to claim 6, characterized in that, The specific operation of S3 is as follows: S3.1 Add the water-extracted fluid extract described in S1 to the modified film-forming material, and then stir. While stirring, add the alcohol-extracted fluid extract described in S1. After mixing, a drug-containing film-forming matrix material is obtained. S3.

2. A specific mass fraction of a penetration enhancer is added to the drug-containing film-forming matrix material, and the mixture is stirred to obtain a drug film paste.

10. The method for preparing a musk-containing liquid medicated film bandage according to claim 6, characterized in that, The specific operation of S4 is as follows: S4.1 The medicated film slurry described in S3 is subjected to homogenization, degassing, and filtration treatment in sequence; S4.2 In a sterile cleanroom, the medicated film mortar is filled into a specific container and packaged to form a finished product.

Images